# US 2004/0081587 A1 · Marker detection method and apparatus to monitor drug compliance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0081587 A1
- Document ID: US20040081587A1
- Status: Published application
- Kind: A1
- Application number: 10/722,620
- Filed: 2003-11-26
- Published: 2004-04-29
- Earliest claimed: 1999-11-08
- Assignees: University of Florida Research Foundation, Inc.
- Inventors: Richard J. Melker; Samsun Lampotang; David N. Silverman
- Web page: https://patentgrep.com/patent/US20040081587A1

## CPC

- A61B 5/411: {Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance}
- A61B 5/00: Measuring for diagnostic purposes (radiation diagnosis A61B6/00; diagnosis by ultrasonic, sonic or infrasonic waves A61B8/00); Identification of persons
- A61B 5/082: {Evaluation by breath analysis, e.g. determination of the chemical composition of exhaled breath (A61B5/083, A61B5/091 take precedence)}
- A61B 5/4833: {Assessment of subject's compliance to treatment}
- G01N 33/497: of gaseous biological material, e.g. breath
- Y10T 436/104165: Lipid, cholesterol, or triglyceride standard or control
- Y10T 436/13: Tracers or tags
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention includes a method and apparatus for monitoring drug compliance by detecting markers, such as odors, upon exhalation by a patient after medication is taken, wherein such markers result either directly from the medication itself or from an additive combined with the medication. In the case of olfactory markers, the invention preferably utilizes electronic sensor technology, such as the commercial devices referred to as “artificial noses” or “electronic noses,” to non-invasively monitor compliance. The invention further includes a reporting system capable of tracking compliance (remote or proximate) and providing the necessary alerts.

## Claims

### Claim 1

A method of determining patient compliance in taking a medication, comprising
providing to the patient a combination of a medication and a detectable marker, the combination to be taken by the patient as a result of the patient's own actions,
obtaining a sample of the patient's gaseous exhaled breath; and
analyzing the sample of the patient's breath to confirm the presence or absence of said marker in the patient's breath as an indication of patient compliance or non-compliance in taking the medication; wherein the medication is to be taken by volitional patient action at specified times.

### Claim 2 (depends on 1)

The method of claim 1 wherein the medication itself comprises said detectable marker.

### Claim 3 (depends on 1)

The method of claim 1 wherein the marker is an odorous substance.

### Claim 4 (depends on 3)

The method of claim 3 wherein the sample of the patient's breath is analyzed to confirm the presence of said marker by sensor technology selected from semiconductor gas sensor technology, conductive polymer gas sensor technology, or surface acoustic wave gas sensor technology.

### Claim 5 (depends on 4)

The method of claim 4 wherein the sensor technology produces a unique electronic fingerprint to characterize the marker such that the presence and concentration of the marker is determined.

### Claim 6 (depends on 1)

The method of claim 1 wherein the marker is a flavor ingredient selected from trans-Anethole (1-methoxy-4-propenyl benzene)—anise; Benzaldehyde (benzoic aldehyde)—bitter almond; Butyl isobutyrate (n-butyl 2, methyl propanoate)—pineapple; Cinnamaldehyde (3-phenylpropenal)—cinnamon; Citral (2-trans-3, 7-dimenthyl-2, 6-octadiene-1-al)—citrus; Menthol (1-methyl-4-isopropylcyclohexane-3-ol)—menthol; and alpha-Pinene (2, 6, 6-trimethylbicyclo-(3,1,1)-2-heptene)—pine.

### Claim 7 (depends on 1)

The method of claim 1 wherein the sample of the patient's breath is analyzed to confirm the presence of said marker by a spectrophotometer.

### Claim 8 (depends on 1)

The method of claim 1 wherein the sample of the patient's breath is analyzed to confirm the presence of said marker by mass spectrometer.

### Claim 9 (depends on 1)

The method of claim 1 wherein the marker is an additive combined with the medication.

### Claim 10 (depends on 1)

The method of claim 1 wherein the marker is a coating on the medication.

### Claim 11 (depends on 10)

The method of claim 10 wherein a substance to stimulate salivation is included with the marker.

### Claim 12 (depends on 1)

The method of claim 1 wherein the marker is included with a liquid medication.

### Claim 13 (depends on 1)

The method of claim 1 wherein the marker is included with a pulmonary delivered medication.

### Claim 14 (depends on 1)

The method of claim 1 wherein the marker is included with an intranasal delivered medication.

### Claim 15 (depends on 1)

The method of claim 1 wherein the marker is included with intravenously delivered medication.

### Claim 16 (depends on 1)

The method of claim 1 further comprising the step of recording data resulting from analysis of the sample of the patient's breath.

### Claim 17 (depends on 1)

The method of claim 1 further comprising the step of transmitting data resulting from the analysis of the sample of the patient's breath.

### Claim 18 (depends on 1)

The method of claim 1 where the analysis of the sample of the patient's breath includes comparing the marker sensed in the sample of the patient's breath with a predetermined signature profile of a specific marker.

### Claim 19 (depends on 18)

The method of claim 18 wherein the predetermined signature profile of a specific marker is associated with a specific drug.

### Claim 20 (depends on 18)

The method of claim 18 wherein the predetermined signature profile of a specific marker is associated with a class of drugs.

### Claim 21 (depends on 1)

The method of claim 1 further comprising the step of capturing the sample of the patient's breath in a vessel prior to analysis.

### Claim 22 (depends on 1)

The method of claim 1 further comprising the step of dehumidifying the sample of the patient's breath prior to analysis.

### Claim 23 (depends on 1)

The method of claim 1 wherein the marker first reacts with enzymes in the patient's mouth to be detectable.

### Claim 24 (depends on 1)

The method of claim 1 wherein the marker first reacts with acids in the patient's stomach to be detectable.

### Claim 25 (depends on 1)

The method of claim 1 wherein the marker is absorbed in the patient's gastrointestinal tract and excreted in the lungs.

### Claim 26 (depends on 1)

The method of claim 1 wherein the data resulting from analysis of the sample of the patient's breath includes marker concentration and, thus, medication concentration.

### Claim 27 (depends on 1)

The method of claim 1 further comprising the step of identifying a baseline marker spectrum for the patient prior to the patient's taking of the medication.

### Claim 28 (depends on 1)

The method of claim 1 wherein said analysis further includes detecting exhalation of the patient's breath with a sensor.

### Claim 29

A method of producing medication which is detectable as an indication of patient compliance in taking the medication comprising the steps of:
identifying a marker substance detectable in gaseous exhaled breath, and
producing a medication combined with said detectable marker substance, said medication to be taken by volitional patient action at specified times whereby subsequent analysis of the patient's breath will confirm the presence of said marker substance and thus the patient's compliance in taking said medication.

### Claim 30 (depends on 1)

The method of claim 1 wherein the marker is included with transdermally delivered medication.
